# Denosumab Biosimilar Injection in Post Menopausal Women With Osteoporosis

> **NCT05419427** · PHASE3 · UNKNOWN · sponsor: **Lambda Therapeutic Research Ltd.** · enrollment: 552 (estimated)

## Conditions studied

- Osteoporosis, Postmenopausal

## Interventions

- **DRUG:** Denosumab
- **DRUG:** Denosumab-Ref

## Key facts

- **NCT ID:** NCT05419427
- **Lead sponsor:** Lambda Therapeutic Research Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-11-11
- **Primary completion:** 2024-09-11
- **Final completion:** 2024-11-24
- **Target enrollment:** 552 (ESTIMATED)
- **Last updated:** 2023-10-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05419427

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05419427, "Denosumab Biosimilar Injection in Post Menopausal Women With Osteoporosis". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT05419427. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*